Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 106 to 120 of 166 results for pembrolizumab

  1. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

    Technology appraisal guidance
    Discontinued

  2. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

    Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA562

  3. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    In development [GID-TA10851] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued [GID-TA10208]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued [GID-TA10110]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477]

    Awaiting development [GID-TA11599] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808

    Awaiting development [GID-TA11200] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued [GID-TA10857]

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    In development [GID-TA10906] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    2 September 2020
    View recommendations

    Sections for TA645

  11. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA866

  12. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued [GID-TA10567]

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

    Technology appraisal guidance
    Discontinued

  14. Past appeals and decisions

    nanoparticles (with gemcitabine, 1st line) [ID680] 16 March 2015 TBC Pembrolizumab for treating locally advanced or metastatic...

  15. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

    Technology appraisal guidance
    Discontinued